India
· Delayed Price · Currency is INR Gland Pharma Statistics
Total Valuation
Gland Pharma has a market cap or net worth of INR 262.36 billion. The enterprise value is 237.42 billion.
| Market Cap | 262.36B |
| Enterprise Value | 237.42B |
Important Dates
The next estimated earnings date is Tuesday, May 20, 2025.
| Earnings Date | May 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Gland Pharma has 164.76 million shares outstanding. The number of shares has increased by 0.01% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 164.76M |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 34.84% |
| Float | 73.18M |
Valuation Ratios
The trailing PE ratio is 37.24 and the forward PE ratio is 27.55. Gland Pharma's PEG ratio is 1.60.
| PE Ratio | 37.24 |
| Forward PE | 27.55 |
| PS Ratio | 4.58 |
| PB Ratio | 2.98 |
| P/TBV Ratio | 3.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 1.60 |
Enterprise Valuation
| EV / Earnings | 33.71 |
| EV / Sales | 4.14 |
| EV / EBITDA | 17.16 |
| EV / EBIT | 26.22 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.24 |
| Debt / FCF | n/a |
| Interest Coverage | 22.58 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 6.37% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 13.59M |
| Profits Per Employee | 1.67M |
| Employee Count | 4,217 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.07% in the last 52 weeks. The beta is 0.29, so Gland Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -11.07% |
| 50-Day Moving Average | 1,554.58 |
| 200-Day Moving Average | 1,763.98 |
| Relative Strength Index (RSI) | 51.34 |
| Average Volume (20 Days) | 416,200 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Gland Pharma had revenue of INR 57.29 billion and earned 7.04 billion in profits. Earnings per share was 42.76.
| Revenue | 57.29B |
| Gross Profit | 31.72B |
| Operating Income | 9.05B |
| Pretax Income | 10.73B |
| Net Income | 7.04B |
| EBITDA | 13.65B |
| EBIT | 9.05B |
| Earnings Per Share (EPS) | 42.76 |
Balance Sheet
The company has 28.20 billion in cash and 3.27 billion in debt, giving a net cash position of 24.93 billion or 151.34 per share.
| Cash & Cash Equivalents | 28.20B |
| Total Debt | 3.27B |
| Net Cash | 24.93B |
| Net Cash Per Share | 151.34 |
| Equity (Book Value) | 87.88B |
| Book Value Per Share | 533.63 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 55.37%, with operating and profit margins of 15.80% and 12.30%.
| Gross Margin | 55.37% |
| Operating Margin | 15.80% |
| Pretax Margin | 18.72% |
| Profit Margin | 12.30% |
| EBITDA Margin | 23.82% |
| EBIT Margin | 15.80% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 20.00, which amounts to a dividend yield of 1.26%.
| Dividend Per Share | 20.00 |
| Dividend Yield | 1.26% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -0.01% |
| Shareholder Yield | 1.25% |
| Earnings Yield | 2.68% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |